These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 38914777)

  • 1. Paradoxical psoriasis induced by IL-17 inhibitors: a case series of patients with axial spondyloarthritis and a systematic literature review.
    Chaitidis N; Papadopoulou Z; Varvara ST; Panagiotidis M; Katsigianni I; Sakellariou GT
    Rheumatol Int; 2024 Nov; 44(11):2659-2668. PubMed ID: 38914777
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Etanercept in Axial Spondyloarthritis, Psoriatic Arthritis, and Plaque Psoriasis: Real-World Outcome Data from German Non-interventional Study ADEQUATE.
    Feist E; Baraliakos X; Behrens F; Thaçi D; Plenske A; Klaus P; Meng T
    Rheumatol Ther; 2024 Apr; 11(2):331-348. PubMed ID: 38308727
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Paradoxical Psoriasis and Worsening Spondylitis Due to Secukinumab in a Patient With Ankylosing Spondylitis: A Case Report and Literature Review.
    Alnaqbi KA; Al Zeyoudi J; Fazal F; Alhaj OM; Jassim I; Albreiki FA
    Cureus; 2023 Dec; 15(12):e50726. PubMed ID: 38111814
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term safety of Ixekizumab in adults with psoriasis, psoriatic arthritis, or axial spondyloarthritis: a post-hoc analysis of final safety data from 25 randomized clinical trials.
    Deodhar A; Blauvelt A; Lebwohl M; Feely M; Kronbergs A; Eberhart N; Zhu D; Inman E; Grace E; Holzkaemper T; Rahman P; Marzo-Ortega H; Papp KA; Merola JF; Gottlieb AB; Schwartzman S
    Arthritis Res Ther; 2024 Feb; 26(1):49. PubMed ID: 38347650
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment persistence of interleukin-17 inhibitor class drugs among patients with psoriasis in Japan: a retrospective database study.
    Wang C; Torisu-Itakura H; Hanada T; Matsuo T; Cai Z; Osaga S; Aranishi T
    J Dermatolog Treat; 2023 Dec; 34(1):2229465. PubMed ID: 37403477
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Paradoxical psoriasis induced by IL-17 antagonists.
    Wang Y; Yang F; Wang R; Luo S
    Indian J Dermatol Venereol Leprol; 2024; 90(5):623-631. PubMed ID: 38594973
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
    Sbidian E; Chaimani A; Garcia-Doval I; Doney L; Dressler C; Hua C; Hughes C; Naldi L; Afach S; Le Cleach L
    Cochrane Database Syst Rev; 2021 Apr; 4(4):CD011535. PubMed ID: 33871055
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterisation of patients with axial psoriatic arthritis and patients with axial spondyloarthritis and concomitant psoriasis in the SCQM registry.
    Ciurea A; Götschi A; Kissling S; Bernatschek A; Bürki K; Exer P; Nissen MJ; Möller B; Scherer A; Micheroli R
    RMD Open; 2023 Jun; 9(2):. PubMed ID: 37277211
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug Survival of Interleukin (IL)‑17 and IL‑23 Inhibitors for the Treatment of Psoriasis: A Retrospective Multi‑country, Multicentric Cohort Study.
    Torres T; Puig L; Vender R; Yeung J; Carrascosa JM; Piaserico S; Gisondi P; Lynde C; Ferreira P; Bastos PM; Dauden E; Leite L; Valerio J; Del Alcázar-Viladomiu E; Rull EV; Llamas-Velasco M; Pirro F; Messina F; Bruni M; Licata G; Ricceri F; Nidegger A; Hugo J; Mufti A; Daponte AI; Teixeira L; Balato A; Romanelli M; Prignano F; Gkalpakiotis S; Conrad C; Lazaridou E; Rompoti N; Papoutsaki M; Nogueira M; Chiricozzi A
    Am J Clin Dermatol; 2022 Nov; 23(6):891-904. PubMed ID: 35976568
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment Patterns and Healthcare Resource Utilization Among Newly Diagnosed Psoriasis, Psoriatic Arthritis, Axial Spondyloarthritis, and Hidradenitis Suppurativa Patients with Past Diagnosis of an Inflammatory Condition: A Retrospective Cohort Analysis of Claims Data in the United States.
    Hopson S; Gibbs LR; Syed S; Low R; McClung L; Beaty S
    Adv Ther; 2023 Oct; 40(10):4358-4376. PubMed ID: 37486558
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Efficacy of Biologic Therapy for the Management of Palmoplantar Psoriasis and Palmoplantar Pustulosis: A Systematic Review.
    Sanchez IM; Sorenson E; Levin E; Liao W
    Dermatol Ther (Heidelb); 2017 Dec; 7(4):425-446. PubMed ID: 29143230
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment Patterns for Targeted Therapies, Non-Targeted Therapies, and Drug Holidays in Patients with Psoriasis.
    Armstrong A; Xia Q; John AR; Patel V; Seigel L
    Dermatol Ther (Heidelb); 2022 Sep; 12(9):2087-2103. PubMed ID: 35947341
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Paradoxical reaction to IL-17A inhibitor: a case report and literature review.
    Ren J; Deng L; Guo S; Liu H
    Front Med (Lausanne); 2024; 11():1364127. PubMed ID: 38695018
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
    Sbidian E; Chaimani A; Afach S; Doney L; Dressler C; Hua C; Mazaud C; Phan C; Hughes C; Riddle D; Naldi L; Garcia-Doval I; Le Cleach L
    Cochrane Database Syst Rev; 2020 Jan; 1(1):CD011535. PubMed ID: 31917873
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-World Discontinuation and Switching Patterns for Interleukin-Inhibitor Treatments in Patients with Moderate-to-Severe Psoriasis in Japan.
    Tada Y; Soliman AM; Ishii K; Sakuma R; Puig L; Davis M; Nunag D; Pinter A; Imafuku S
    Dermatol Ther (Heidelb); 2024 Jan; 14(1):99-114. PubMed ID: 38019410
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adalimumab Biosimilar-Induced Severe Paradoxical Palmoplantar Pustulosis in a Patient with Psoriasis and Psoriatic Arthritis Successfully Treated with Ixekizumab.
    Gkalpakiotis S; Fridman M; Tivadar S
    Dermatol Ther (Heidelb); 2022 Feb; 12(2):605-609. PubMed ID: 35067854
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-IL-17 Agents in the Treatment of Axial Spondyloarthritis.
    Atzeni F; Carriero A; Boccassini L; D'Angelo S
    Immunotargets Ther; 2021; 10():141-153. PubMed ID: 33977094
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of switches within the class of IL-17 inhibitors: An analysis of data from the Czech nationwide registry of psoriatic patients receiving biological/targeted therapy (BIOREP).
    Tichy M; Kojanova M; Velackova B; Dolezal T; Gkalpakiotis S; Cetkovska P;
    Dermatol Ther; 2022 Oct; 35(10):e15772. PubMed ID: 36065488
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-marketing surveillance data.
    Deodhar A; Mease PJ; McInnes IB; Baraliakos X; Reich K; Blauvelt A; Leonardi C; Porter B; Das Gupta A; Widmer A; Pricop L; Fox T
    Arthritis Res Ther; 2019 May; 21(1):111. PubMed ID: 31046809
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Short-Term Efficacy and Safety of IL-17, IL-12/23, and IL-23 Inhibitors Brodalumab, Secukinumab, Ixekizumab, Ustekinumab, Guselkumab, Tildrakizumab, and Risankizumab for the Treatment of Moderate to Severe Plaque Psoriasis: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials.
    Bai F; Li GG; Liu Q; Niu X; Li R; Ma H
    J Immunol Res; 2019; 2019():2546161. PubMed ID: 31583255
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.